9 years (SD, 10.0), 57.5% (2,123 of 3,690) were male, and 62.8% (2,317 of 3,690) had ever injected drugs. The mean follow-up duration of this cohort was 5.7 years (range: 3 days to 12.9 years). A total of 2,962 hospital episodes were observed during FU of our treatment cohort. Of these, 1,005 (34%) were liver-related (based on main and supplementary discharge codes) hospital episodes (103 episodes find more from 47 SVR patients and 902 episodes from 266 non-SVR patients). Eighty-eight patients died during FU, of which 55 deaths (63%) were liver related (based
on main and supplementary discharge codes). Rates of liver-related, non-liver-related, and all-cause outcomes were all lower among SVR patients, compared to non-SVR patients (Table 3). This was most apparent, however, for liver-related outcomes (hospital episode crude hazard ratio [CHR]: 0.20; 95% CI: 0.13-030; mortality CHR: 0.19; 95% CI: 0.08-0.48). In univariate analyses of treatment patients (Table 4), variables were significantly associated (P < 0.10) with
time to a liver-related hospital episode (defined on the basis of main and supplementary discharge codes), and thus included in multivariate analyses, were as follows: SVR, age group at study entry, Asian ethnicity, ever injector, diagnosed cirrhotic, alcohol-related hospitalization, and mean ALT post-treatment >50 IU/L. Variables not significantly associated with time to a liver-related hospital episode in univariate analyses included gender and genotype. In multivariate regression (Table 4), individuals with Ivacaftor purchase Thiamine-diphosphate kinase a significantly reduced risk of a liver-related hospital episode included those with an SVR, compared to a non-SVR (adjusted hazard ratio [AHR]: 0.22; 95% CI: 0.15-0.34), and those who had ever injected, compared to never injected (0.70; 95% CI: 0.50-0.98). Although those with a significantly increased risk of a liver-related hospital episode
included those older in age at study entry (30-39 years, compared to <30; 1.68; 95% CI: 0.89-3.19; 40-49 years, compared to <30: 2.39; 95% CI: 1.33-4.32; 50-59 years, compared to <30: 2.81; 95% CI: 1.46-5.40; and >=60 years, compared to <30: 2.84; 95% CI: 1.36-5.94), of Asian ethnicity (2.13; 95% CI: 1.27-3.58), diagnosed cirrhotic (3.38; 95% CI: 2.42-4.71), and with an alcohol-related hospitalization during FU (4.27; 95% CI: 2.69-6.77). Our results did not significantly differ when a liver-related hospital episode was defined on the basis of main discharge code(s) only. In univariate analyses of treatment patients (Table 5), variables significantly were associated (P < 0.10) with time to a liver-related death (defined on the basis of codes for main and supplementary causes), and thus included in multivariate analyses, were as follows: SVR, age at study entry, diagnosed cirrhotic, and alcohol-related hospitalization.